Clinical Trial Update: A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for BOMedemstat in advanced myeloid malignancies (AML and MDS) across Phase 1/2, with and without ATRA; study status completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Bomedemstat (IMG-7289/MK-3543) (bomedemstat)

Snippet

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-07-11